Yiduodi Tablets

This product is a blood lipid regulating drug of clofibric acid derivatives. Its mechanism of lowering blood lipids is not yet fully understood. It may reduce the cAMP content in liver microsomes, increase the activity of lipoprotein esterase, and decompose lipids in lipoproteins. Experimental and clinical studies have shown that this product reduces blood cholesterol and triglycerides and increases blood high-density lipoprotein. In addition, this product also has anti-platelet aggregation and anti-thrombotic effects and reduces blood uric acid.

Main ingredients: The main ingredients of this product and their chemical names are: 2-methyl-2-(4-chlorophenoxy)-propionic acid, 2-(1,2,3,6-tetrahydro-1,3-dimethyl-2,6-dioxo-7H-purinyl)ethyl ester. Molecular formula: C19H21ClN4O5 Molecular weight: 420.85

This product is used to treat hypercholesterolemia.

This product should be taken orally after or during meals. If it is ineffective after taking this product for 3 months, it should be discontinued. The usual dosage for adults is 0.25g orally once, twice a day, which can be increased to 0.25g once, 3 times a day with the treatment response. If combined with hyperuricemia, 0.25g once, 3 times a day can be taken at the beginning. After treatment, if blood lipids are normal, 0.25g once, 2 times a day can be used to maintain.

1. The most common adverse reactions are gastrointestinal discomfort, such as indigestion, nausea, fullness, stomach discomfort, etc. Other less common adverse reactions include headache, dizziness, fatigue, rash, itching, impotence, anemia and leukopenia. Some cases have elevated blood aminotransferase. 2. This product is a derivative of clofibric acid, which may cause myositis, myopathy and rhabdomyolysis syndrome, leading to elevated blood creatine phosphokinase; rhabdomyolysis occurs, mainly manifested by myalgia combined with elevated blood creatine phosphokinase, myoglobinuria, and can lead to renal failure, but it is rare; in patients with nephrotic syndrome and other renal damage that lead to decreased blood albumin or patients with hyperthyroidism, the risk of myopathy increases. 3. This product increases the risk of cholelithiasis; clofibric acid derivatives can affect the metabolism of steroids in three ways. They can inhibit the synthesis of cholesterol, inhibit the synthesis of bile acids, and enhance the excretion of cholesterol from bile. The latter two factors can increase the cholesterol saturation in bile, thus may cause gallstones to form in some patients, but there may also be other influencing factors.

1. Patients who are allergic to edoxalate are contraindicated. 2. Patients with hepatic insufficiency or primary biliary cirrhosis are contraindicated. This product can promote increased cholesterol excretion and increase the already high cholesterol level. 3. Patients with severe renal insufficiency are contraindicated because taking this product may cause rhabdomyolysis and severe hyperkalemia in patients with renal insufficiency; patients with nephrotic syndrome causing hypoalbuminemia are contraindicated because they have an increased risk of myopathy. 4. Patients with gallbladder disease and cholelithiasis are contraindicated. This product can aggravate the symptoms of gallbladder disease and require surgery. 5. Patients with recent myocardial infarction or epilepsy are contraindicated.

1. This product can enhance the effect of oral anticoagulants. When used with it, you should pay attention to reducing the dose of oral anticoagulants. Its mechanism of action is still uncertain. It may be because this product can replace warfarin and other drugs from their protein binding sites, thereby enhancing their effects. 2. When this product is used in combination with other drugs with high protein binding rates, it can also replace them from the protein binding sites, resulting in enhanced effects, such as tolbutamide and other sulfonylurea hypoglycemic drugs, phenytoin, furosemide, etc. When taking the above drugs during lipid-lowering treatment, the doses of hypoglycemic drugs and other drugs should be adjusted. 3. The combined use of clofibric acid derivatives and HMG-CoA reductase inhibitors such as pravastatin and simvastatin to treat hyperlipidemia will increase the risk of severe muscle toxicity of both, and joint use should be avoided as much as possible. 4. When this product is used in combination with immunosuppressants such as cyclosporine, it can increase the latter's blood drug concentration and nephrotoxicity. You should also pay attention when this product is used in combination with other nephrotoxic drugs. 5. This product contains theophylline. Pay attention to the reaction when used with theophylline.

Keep sealed and protected from light.

0.25g

Harbin Pharmaceutical Group Co., Ltd. GENERAL Pharm. FACTORY

• Founded in:

  1994-05-19

• Address:

  No. 388, Hahei Highway, Hulan District (production base No. 109, Xuefu Road, Nangang District, No. 1, Junmin Street, Xiangfang District)

• Tax NO.:

  912301008280277137

• Registered Funds:

  -

• Website:

  Log in to view

• Email:

  Log in to view